Ubiquitin-dependent mechanisms have emerged as essential regulatory elements controlling cellular levels of Smads and TGFb-dependent biological outputs such as epithelial-mesenchymal transition (EMT). In this study, we identify a HECT E3 ubiquitin ligase known as WWP2 (Full-length WWP2-FL), together with two WWP2 isoforms (N-terminal, WWP2-N; C-terminal WWP2-C), as novel Smad-binding partners. We show that WWP2-FL interacts exclusively with Smad2, Smad3 and Smad7 in the TGFb pathway. Interestingly, the WWP2-N isoform interacts with Smad2 and Smad3, whereas WWP2-C interacts only with Smad7. In addition, WWP2-FL and WWP2-C have a preference for Smad7 based on protein turnover and ubiquitination studies. Unexpectedly, we also find that WWP2-N, which lacks the HECT ubiquitin ligase domain, can also interact with WWP2-FL in a TGFb-regulated manner and activate endogenous WWP2 ubiquitin ligase activity causing degradation of unstimulated Smad2 and Smad3. Consistent with our protein interaction data, overexpression and knockdown approaches reveal that WWP2 isoforms differentially modulate TGFb-dependent transcription and EMT. Finally, we show that selective disruption of WWP2 interactions with inhibitory Smad7 can stabilise Smad7 protein levels and prevent TGFb-induced EMT. Collectively, our data suggest that WWP2-N can stimulate WWP2-FL leading to increased activity against unstimulated Smad2 and Smad3, and that Smad7 is a preferred substrate for WWP2-FL and WWP2-C following prolonged TGFb stimulation. Significantly, this is the first report of an interdependent biological role for distinct HECT E3 ubiquitin ligase isoforms, and highlights an entirely novel regulatory paradigm that selectively limits the level of inhibitory and activating Smads.
Introduction
The TGFb family controls a range of normal biological activities including cell growth, migration, differentiation and apoptosis (Heldin et al, 2009) . Overactivation of TGFb signalling is also implicated in many human diseases including fibrosis, heart disease and cancer. These pathologies are increasingly being linked to the TGFb-dependent induction of cellular trans-differentiation and epithelial-mesenchymal transition (EMT) (Zavadil and Bo¨ttinger, 2005; Xu et al., 2009b) . TGFbs signal through Ser/Thr kinase receptors that phosphorylate TGFb/activin/BMP pathway restricted R-Smads (Smads 1, 2, 3, 5, 8) . Receptors for activin/TGFb activate Smad2 and Smad3, and receptors for BMPs activate Smad1, Smad5 and Smad8. Down-regulation of TGFb signalling is achieved, in part, by feedback mechanisms involving the inhibitory Smad6 and Smad7. Deciphering mechanisms that fine-tune and modulate Smads is critical for understanding TGFb biological activity and complexity, and ubiquitin-dependent mechanisms have emerged as key regulatory elements in the control of cellular levels of both TGFb receptors and Smads (Lo¨nn et al., 2009) .
Protein ubiquitination involves a cascade of events catalysed sequentially by E1 (ubiquitin-activating), E2 (ubiquitin-conjugating) and E3 (ubiquitin ligase) enzymes. The human genome contains two E1 enzymes generated by alternate splicing of a single gene, B30 E2 enzymes, and over 600 E3 ligases (Li et al., 2008) . E3 ubiquitin ligases are key to target substrate specificity, and these can be segregated primarily into RING-type and HECT-domain ligases. Within the HECT-domain, E3 ligases is a small sub-group known as the NEDD4 family. Smurf1 is a NEDD4 family E3 ligase and this was the first E3 ligase to be implicated in the TGFb signalling pathway. Smurf1 binds and regulates levels of unstimulated BMP-regulated Smads 1 and 5 (Zhu et al., 1999) . Smurf2 binds and ubiquitinylates primarily phospho-Smads 1 and 2 (Bonni et al., 2001) , but is also recruited to the type-1 TGFb receptor via Smad7 (Kavsak et al., 2000) . The NEDD4 sub-group of HECT E3 ligases comprise three functional domains: an Nterminal Ca 2 þ /phospholipid-binding C2 domain for membrane binding, a central region containing up to four WW (double-tryptophan) domains, and a C-terminal HECT domain for ubiquitin protein ligation (Bernassola et al, 2008) . The WW domains are essential for target specificity and they interact with PPXY (also known as -PY) motifs, phospho-Ser-Pro and Pro-Arg containing sequences in target substrates (Pirozzi et al., 1997; Lu et al., 1999) . WWP2, which contains four WW domains, is the least well characterised of the HECT sub-family, although it has been implicated in regulating the turnover of the epithelial sodium channel (McDonald et al, 2002) , the large subunit of RNA polymerase II (Li et al., 2007) , divalent metal-ion transporter DMT1 (Foot et al., 2008) , and the stem-cell-specific transcription factor Oct4 (Xu et al., 2004 (Xu et al., , 2009a .
In this study, we identify full-length WWP2 (WWP2-FL) and two novel WWP2 isoforms, WWP2-N and WWP2-C as Smad interacting proteins that selectively bind Smad2/3 and Smad7 and regulate TGFb-induced biological responses. Mechanistically, we show that expression of WWP2-N can modulate TGFb signalling activity by interacting with WWP2-FL and activating it's intrinsic ubiquitin ligase activity. Collectively, our data indicate that the regulation of WWP2 isoform expression could provide a novel switch mechanism controlling cell context-dependent and disease-specific TGFb signalling activity.
Results

WWP2 interacts with Smad2, Smad3 and Smad7
The WWP2 HECT E3 ubiquitin ligase emerged as a candidate Smad3-binding partner in a previous yeast two-hybrid screen of a mouse brain complementory DNA expression library using the MH1 and linker regions of Smad3 as bait (Wicks et al., 2005) . Scrutiny of Mammalian Gene Collection (MGC) databases containing sequence-validated full-length protein-coding complementary DNA clones identified a unique and interesting feature of WWP2 in that there are three WWP2 isoforms arising from the same gene locus: full-length WWP2 (WWP2-FL, 870aa), an N-terminal isoform (WWP2-N, 336aa) presumably generated by failure to splice-out intron 9-10, and a C-terminal isoform (WWP2-C, 440aa) that is likely to be generated from a second promoter within intron 10-11 ( Figure 1a ). To independently confirm expression of these distinct and novel WWP2 isoforms we first used isoform-specific primers and reverse transcriptase-PCR (RT-PCR) to detect transcripts in Colo-357 pancreatic carcinoma cells that are known to be TGFb responsive (Levy and Hill, 2005) . Interestingly, expression of FL-WWP2 seems to be induced by TGFb, peaking after 2-days stimulation and is absent after 4 days (Figure 1b) . In contrast, WWP2-N expression does not change following TGFb treatment, but does also disappear after 4 days ( Figure 1b ). Thus far, we have not been able to clearly detect the WWP2-C isoform in Colo-357 cells under the same experimental conditions, although we have seen robust expression in cartilage-derived ATDC5 cells that differentiate following prolonged exposure to insulin (Figure 1c) . Therefore, these data demonstrate that all three WWP2 isoforms exist, and also suggest that they may be regulated independently in a cell-contextdependent manner.
To further characterise and confirm interactions between Smads and FL-WWP2 identified during the yeast two-hybrid screen, we then used co-expression of epitope-tagged proteins and co-immunoprecipitation experiments. Immunoprecipitation of WWP2 from cell lysates revealed strong binding of WWP2-FL to Smad2, Smad3 and Smad7, but not to BMP-regulated Smad1 and Smad5 (Figure 1d ). Flag-WWP2-FL interactions with HA-Smad2 and HA-Smad3, and to some extent HA-Smad7, were also enhanced when cells were TGFb stimulated ( Figure 1d ). Next, we examined whether WWP2 interacts with Smads endogenously at physiological levels of expression. In anti-WWP2 immunoprecipitates of lysates from Colo-357 cells, we observed both Smad2 and Smad3 co-precipitating with WWP2 in a TGFb-dependent manner (Figure 1e ). Specificity of these interactions was confirmed using stable and inducible small hairpin RNA-mediated knockdown of WWP2-FL, in which Smad2 and Smad3 are both absent in WWP2 immunoprecipitated complexes (Figure 1e ). Smad7 also bound to WWP2 endogenously, although there are higher molecular weight Smad7 reactive bands following TGFb stimulation that are not seen in WWP2-FL knockdown cells (Figure 1f ). This may reflect low and undetectable levels of Smad7 due to enhanced Smad7 turnover following exposure to TGFb, or that endogenous Smad7 bound to WWP2 is predominantly polyubiquitinated.
WWP2 isoforms bind differentially to R-Smads and I-Smads
As individual N-and C-terminal WWP2 isoforms contain separate and distinct WW domains, we next examined whether these domains conferred any differential binding specificity for individual Smad proteins. We co-expressed Flag-WWP2-FL, Flag-WW2-N or Flag-WWP2-C together with HA-Smad3, immunoprecipitated cell lysates with HA antibody and then probed western blots with FLAG antibody. Interestingly, WWP2-N, as well as WWP2-FL, but not WWP2-C, interact with Smad3 in a TGFb-dependent manner ( Figure 2a ). As WWP2-N contains the C2 domain and only a single WW domain (WW1), we surmise that WW1 in WWP2-N harbours the Smad3 interaction motif. We then used a series of Smad3 deletion constructs to map the region in Smad3 that binds the WW1 domain of WWP2-N. Truncated HA-Smad3 mutants comprising either residue 1-395, 1-240 or 1-180 were co-expressed in HEK-293 cells with Flag-WWP2-N, cell lysates immunoprecipitated with HA antibody and western blots probed with Flag antibody. Smad3 1-395 and Smad3 1-240 bound efficiently to WWP2-N but not Smad3 (Figure 2a ). The site in Smad3 that binds to WWP2-N is therefore within residues 180-240, which include the WW-binding PPGY motif in the linker region. Interestingly, Smad3 C-terminal deletion proteins Smad3 1-395 and Smad3 1-240 interact independently of TGFb stimulation. It is likely that this is due to removal of the receptor phosphorylation sites at the C-terminal SSVS motif relieving auto-inhibitory MH1/MH2 domain interactions that normally repress Smad3 function (Hata et al., 1997) , and this supports our finding that the interactions between WWP2 isoforms and Smad3 is TGFb-dependent. We next examined WWP2 isoform interactions with Smad2 and Smad7 using the same co-immunoprecipitation approach. Smad2 bound to WWP2-FL and WWP2-N, but not WWP2-C (Figure 2b ). However, it is WWP2-C together with WWP2-FL, but not WWP2-N, which interact with Smad7 in a TGFb-dependent manner (Figure 2c ). Smad7 GST pull-down studies confirmed that WW4 domain in WWP2 interacts with the PPXY motif in Smad7 (Supplementary Figure S1) . Therefore, it is the WW4 domain of WWP2-C that interacts with Smad7, and this difference in WW domain-binding specificity may be due to the different composition of the PPXY motif sequence in Smad7 relative to Smad2 and Smad3.
WWP2 promotes Smad protein turnover and ubiquitination WWP2 is an E3 ubiquitin ligase that is able to ubiquitinate target substrates and can accelerate proteosomal-dependent protein turnover. To test whether Smad turnover rates are affected by WWP2, we performed cycloheximde chase experiments in HEK-293 cells expressing Flag-tagged Smads. Expression of WWP2 significantly enhanced turnover of Smad2, Smad3 and Smad7 proteins in a TGFb-dependent manner (Figure 3a) . The acceleration of Smad7 turnover was more pronounced than both Smad2 and Smad3, and following 6-h cycloheximide chase Smad7 was undetectable (Figure 3b ). We then tested whether increased levels of ubiquitination could explain the , Genbank accession no. NM_007014), an N-terminal isoform (WWP2-N, 336aa, Genbank accession no. NM_199423) presumably generated by failure to splice-out intron 9-10, and a C-terminal isoform (WWP2-C, 440aa, Genbank accession no. NM_199424) that is likely to be generated from a second internal promoter P2 within intron 10-11. (b) RNA isolated from Colo-357 cells stimulated with TGFb for the indicated number of days, was isolated and reverse transcribed. A measure of 1.25-ng cDNA was used as template DNA in RT-PCR using primers specific for WWP2-FL, WWP2-N and GAPDH. Equal volumes of the PCR products were analysed by agarose gel electrophoresis. (c) RNA isolated from ATDC5 cells and stimulated with insulin for the indicated number of days, was isolated and reverse transcribed (as described in Atsumi et al, 1990) . A measure of 1.25-ng cDNA was used as template DNA in RT-PCR using primers specific for WWP2-FL, WWP2-C and GAPDH. Equal volumes of the PCR products were analysed by agarose gel electrophoresis. (d) HEK-293 cells were co-transfected with plasmids encoding Flag-tagged Smads 1-and HA-tagged WWP2. At 48 h after transfection, the cells were treated with MG132 for 5 h followed by human TGFb (5 ng/ml) or BMP-4 (10 ng/ml) for a further 1 h. Cells were lysed and subjected to immunoprecipitation (IP) with an anti-HA antibody and then analysed by western blotting (WB) with an anti-Flag antibody. Whole-cell lysates were also analysed for positive expression of epitope-tagged proteins and b-actin as indicated (lower panels). (e) 10 7 confluent Colo-357 cells (WWP2-FL small hairpin RNA knockdown) were pretreated with MG132 for 5 h (±Doxycycline), and stimulated with 5 ng/ml TGFb for 1 h. Cleared lysates were immuno-precipitated with 3-mg anti-WWP2 overnight, and analysed for the presence of Smad2 and Smad3. (f) As described in e above, except that cells were pre-treated for 18 h with MG132 and stimulated for 48 h with 5 ng/ml TGFb. Anti-WWP2 immune-complexes were washed and analysed by western blotting for Smad7. WWP2 and actin controls blots are also included.
WWP2 isoforms differentially modulate Smad/TGFb signalling SM Soond and A Chantry enhanced turnover of Smads in the presence of WWP2. HEK-293 cells were transfected with HA-ubiquitin, Flag-tagged WWP2 and Flag-tagged Smads 2, 3 or 7, and cells were stimulated with TGFb for up to 6 h followed by anti-HA immunoprecipitation and antiSmad immunoblotting. Co-expression with WWP2 clearly enhances the formation of Smad2-and Smad3-ubiquitinated complexes (Figure 4a ). Furthermore, Values were then standardized relative to Time ¼ 0 h (which was set to 1), and graphs (±TGFb/±WWP2) were plotted using Excel and optimum best-fit trendlines determined.
WWP2 isoforms differentially modulate Smad/TGFb signalling SM Soond and A Chantry these complexes seem to increase following TGFb stimulation, although as we are not able to resolve unmodified Smads from Smad-mono-ubiquitin species using this gel separation technique, we cannot exclude the possibility that Smad2 and Smad3 are in fact noncovalently associating with ubiquitin in these particular experiments. Interestingly, we find typical high molecular weight laddering and smears with Smad7 within 4 h in the presence of WWP2 suggesting increased polyubiquitination (Figure 4b ). Although we have focussed on a timeframe for TGFb stimulation that correlates with our protein turnover experiments, we do also find Smad2 and Smad3 polyubiquitination following prolonged stimulation (416 h) with TGFb (Supplementary Figure S2 ), although again, we cannot exclude that this is mediated by a separate E3 ligase using this experimental system. Overall, we surmise, that more pronounced Smad7 polyubiquitination by WWP2 does indeed reflect preferred substrate specificity. We next examined whether Smad7 ubiquitination could also be induced by the WWP2-C isoform as WWP2-C interacts exclusively with Smad7 and also contains the E3 ubiquitin ligase catalytic domain. Interestingly, we found that WWP2-C can efficiently induce TGFbdependent Smad7 polyubiquitination, and this modification is more pronounced when compared alongside WWP2-FL in the same experiments ( Figure 4c ). To confirm our findings in transfected cells, we next used in vitro ubiquitination experiments with bacterially expressed WWP2 isoforms and GST-Smad fusion proteins to examine WWP2-FL ubiquitinylating activity against Smad substrates. Smad7 undergoes pronounced poly-ubiquitination in the presence of WWP2-FL and more so with WWP2-C (Figure 4d ). Smad3-GST undergoes moderate ubiquitination in the presence of WWP2-FL and, interestingly, in these in vitro studies this is enhanced in the presence of the WWP2-N isoform that interacts selectively with R-Smads (Figure 4e ).
WWP2-N directly modulates WWP2-FL and induces breakdown of unstimulated R-Smads
As the WWP2-N isoform, which lacks the functional HECT E3 ligase domain, influenced the E3 ubiquitin ligase activity of WWP2-FL towards Smad3 in vitro, we next examined whether WWP2-N expression could influence Smad steady-state levels in the presence of WWP2-FL. Interestingly, dose-dependent expression of WWP2-N can potently reduce Smad2/3 steady-state levels in the presence of WWP2-FL, and independently of TGFb stimulation (Figure 5a ), and cycloheximide , 100 ng HA-Ubiquitin and 100 ng WWP2-FL as indicated. Cells were pre-treated with MG132 for 5 h and then stimulated with TGFb as indicated, followed by anti-HA immunoprecipitation and analysis of ubiquitination species by anti-Smad western blot analysis. (c) HEK293 cells, transfected with 1 mg Smad7-Flag, 100 ng HA-Ubiquitin and either 100 ng WWP2-FL or WWP2-C encoding plasmids (for 48 h), were pre-treated with MG132 for 5 h and then stimulated with TGFb for 3 h followed by anti-HA immunoprecipitation and analysis of Smad7-ubiquitination by Smad7 western blotting. Included are whole-cell lysate (WCL) control blots for WWP2 isoforms and Smad 7. In vitro ubiquitination assays were performed using GST-Smad7 (d) and GST-Smad3 (e) as substrates in the presence of purified WWP2 isoforms (as indicated). All reactions were performed identically at 30 1C for 120 min, before being analysed by western blotting using Smad-specific antibodies. GST-Smad5 was used as a negative control.
chase experiments confirm these findings (Supplementary Figure S3) . In contrast, increased expression of WWP2-N has no effect on Smad7 levels (Figure 5a ). Recent observations suggest that the C-terminal and N-terminal domains of related HECT ligases can form intramolecular auto-inhibitory links (Wiesner et al., 2007; Mund and Pelham, 2009 ). We therefore postulated that truncated WWP2 isoforms might associate with WWP2-FL, and could potentially interfere with intramolecular auto-inhibitory interactions. To test this possibility, we overexpressed Flag-tagged WWP2-FL with HA-tagged isoforms, and used co-immunoprecipitation to identify direct interactions. In the absence of TGFb, WWP2-FL clearly associates with itself and with WWP2-N, and these interactions are disrupted following 1-h treatment of cells with TGFb ( Figure 5b ). The appearance of high molecular weight species also suggests that WWP2-N might regulate WWP2-FL auto-ubiquitination (Figure 5b ), a modification in WWP2 that is associated with ligase domain autoactivation (Mund and Pelham, 2009) . To address whether the reduced levels of Smads in the presence of WWP2-N might reflect enhanced WWP2-FL autoactivation, we examined WWP2-FL auto-ubiquitination using in vitro ubiquitination experiments and find that WWP2-N, as well as WWP2-C, can promote WWP2-FL auto-ubiquitination (Figure 5c ). We then assessed whether the reduced levels of Smads in the presence of WWP2-N might reflect enhanced WWP2-FL autoactivation in vivo, and expressed WWP2-FL together with WWP2-N in the presence of HA-tagged ubiquitin.
Immunoprecipitation of HA-ubiquitin modified Smad2 and Smad3 demonstrates that expression of WWP2-N can increase the level of Smad ubiquination by endogenous WWP2 (Supplementary Figure S4) . Enhanced WWP2-FL activity is concomitant with increased protein turnover seen in cycloheximide chase experiments (Supplementary Figure S5) , and this is In vitro ubiquitination assays were performed using bacterially purified GST-WWP2-FL in the presence of purified WWP2 isoforms. Reactions were performed identically at 30 1C for 120 min, before being analysed by western blotting using WWP2-specific antibodies. (d) Schematic representation indicating that WWP2-FL interacts with WWP2-N to relieve auto-inhibition in the absence of TGFb, and that this complex is released following TGFb stimulation.
WWP2 isoforms differentially modulate Smad/TGFb signalling SM Soond and A Chantry likely to reflect increased WWP2-N-mediated WWP2-FL auto-ubiquitination. Collectively, these data support the notion that WWP2-FL interacts with WWP2-N to induce WWP2-FL auto-activation, and that this complex is released following TGFb stimulation (Figure 5d ), presumably because of TGFb-mediated R-Smad phosphorylation and preferential binding of phospho-R-Smads with WWP2.
WWP2 isoforms differentially modulate TGFb-dependent transcription and EMT
To characterise the effect of WWP2 isoforms on TGFbdependent biological responses, we first used CAGA12-luc and DE-luc luciferase reporter plasmids to measure effects on Smad3-and Smad2-dependent gene expression, respectively. In both instances, there is a significant reduction in TGFb-dependent gene expression in cells overexpressing WWP2-FL in a dose-dependent manner (Figure 6a ). Furthermore, ablation of endogenous WWP2 by transfection of cells with small interfering RNA (siRNA) targeting WWP2 enhances TGFbdependent CAGA12-luc (Smad3) and DE4-luc (Smad2) activity, supporting the notion that WWP2 isoforms can modulate Smad transcriptional responses (Figure 6b ). However, as the WWP2 siRNA could potentially affect endogenous levels of all three WWP2 isoforms, we cannot rule out differential effects on TGFb-dependent gene expression by individual WWP isoforms. Therefore, we next expressed WWP2-C or WWP2-N isoforms and examined their effect on endogenous Smad3-dependent transcription using the CAGA12-luc reporter. Interestingly, over-expression of WWP2-N decreased WWP2 isoforms differentially modulate Smad/TGFb signalling SM Soond and A Chantry CAGA12-luc activity following TGFb stimulation for 6 h in contrast to WWP2-C that showed an opposite response (Figure 6c ). Moreover, expressed WWP2-N showed similar effects on Smad-driven DE4-luc and CAGA12-luc activity following Smad2 and Smad3 overexpression, respectively (Figure 6d ). However, we cannot exclude effects of the truncated WWP2 isoforms functioning independently of endogenous WWP2-FL, although this seems unlikely as in vitro ubiquitination erxperiments do indeed support the idea that WWP2-N functions by activating WWP2-FL (see Figure 4) . To test whether the ubiquitin ligase activity of WWP2 is required for its effect on Smad-mediated transcription we next used a catalytically inactive Cys-838-Ala WWP2 mutant. We find partial reduction in the inhibitory effect on Smad2 and Smad3 gene reporter activity with this mutant compared with wild-type WWP2 (Figure 6e ). This response may be due to activation of endogenous WWP2-FL wild-type enzyme by the overexpressed WWP2-mutant, in keeping with our observation that WWP2 dimerisation is associated with WWP2 autoactivation (see Figure 5 ). To examine further the biological role of WWP2 isoforms in the TGFb pathway, we next assessed the effects of WWP2 isoform expression on TGFb-driven EMT. EMT represents an important differentiation programme that converts static epithelial cells into highly motile and invasive mesenchymal cells, a process that has been linked to cancer-cell proliferation, dispersion and metastasis. We used the Colo-357 pancreatic carcinoma cell line that is known to undergo full EMT upon TGFb stimulation (Ellenrieder et al., 2001; Levy and Hill, 2005 ; see also Supplementary Figure 6) . First, we found that siRNA-mediated knockdown of WWP2 in Colo-357 cells treated with TGFb enhances the expression of vimentin by approximately threefold based on western blotting of cell lysates and causes a moderate increase in Smad 2/3 levels ( Figure 7a ). We then analysed effects of WWP2-FL expression in Colo-357 cells on the TGFb-dependent induction of 
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EMT markers by RT-PCR. To allow for gene-specific temporal differences in expression patterns during EMT, cells were next pre-treated with TGFb for 1, 3 or 4 days before transfection with WWP2-FL. The TGFb-dependent induction of vimentin, snail and fibronectin were significantly inhibited in the presence of WWP2-FL, although these effects were more pronounced following 4 days of pre-treatment with TGFb ( Figure 7b ). This inhibition of TGFb-induced vimentin expression in the presence of expressed WWP2-FL was confirmed by western blot analysis and correlates with a slight reduction in Smad 2/3 levels ( Figure 7c ). We then examined whether WWP2-FL expression 3 days after previous TGFb stimulation could affect a TGFb-mediated EMT program that is already underway, and at the same time also looked at the effect of WWP2-N and WWP2-C expression. Interestingly WWP2-FL, but not WWP2-N, can effectively block TGFb-induced vimentin expression whereas WWP2-C sustains moderately high vimentin levels ( Figure 7d ). Interestingly, and in complete contrast to WWP2-FL expression, treating cells with a small molecule TGFb receptor kinase inhibitor (SB431542) is not able to reverse a TGFb-mediated EMT program that is already in progress (Figure 7d ). Pre-treatment of cells with SB431542 also prevents any WWP2 isoformmediated effects on vimentin expression, presumably due to the TGFb-dependent requirement for WWP2 isoform association with Smads. As WWP2-C contains a single WW4 domain that mediates interactions between WWP2-C (or WWP2-FL) with inhibitory Smad7, we next examined whether TGFb-induced EMT could be moderated by expression of an individual WW4 domain. We therefore expressed an isolated WWP2 WW4 domain tagged with Flag in a dose-dependent manner at 24 h after previous stimulation of Colo-357 cells with TGFb, and 48 h later examined expression levels of both vimentin and Smad7. We find a clear dose-dependent increase in the levels of Smad7 in the presence of WW4 and a concomitant reduction in vimentin (Figure 7e ).
Discussion
We have identified the WWP2 ubiquitin ligase as a novel Smad binding partner that selectively interacts with and ubiquitinates Smads 2, 3 and 7 in the TGFb pathway. Furthermore, we have characterised two additional WWP2 isoforms generated from the WWP2 gene locus, WWP2-N and WWP2-C, and shown isoform-specific interactions with Smad2/3 (WWP2-N) and Smad7 (WWP2-C). Intriguingly, WWP2-N also interacts with WWP2-FL, and this complex is rapidly dissociated after TGFb stimulation. Taken together, our data suggest that WWP2-N can stimulate WWP2-FL auto-activation and auto-ubiquitination in the absence of TGFb leading to increased activity against target substrates Smad2 and Smad3 (but not Smad7), and that Smad7 is a preferred substrate for WWP2-FL and WWP2-C following TGFb stimulation.
To our knowledge, this is the first report of an interdependent biological role for distinct E3 ligase isoforms, and demonstrates an entirely novel regulatory mechanism that selectively fine-tunes levels of both activating and inhibitory Smads. On the basis of our analysis, we propose a model in which expression of individual WWP2 isoforms could serve to drive tissue-and diseasespecific changes in TGFb signalling dynamics and biological responses such as EMT (Figure 8) . First, our data suggests that WWP2-N expression will deplete cellular levels of unstimulated Smads 2/3 presumably due to WWP2-N-dependent disruption of WWP2-FL auto-inhibitory interactions, and subsequent breakdown of these receptor-regulated Smads. Thereafter, following TGFb stimulation, WWP2-N is released from WWP2-FL to interact preferentially with Smads 2/3. Biologically, we predict that this will stabilise the early phase of pathway activation by WWP2-N competing for WWP2-FL:R-Smad interactions, in a process that would be further encouraged by the WWP2-FL-dependent breakdown of inhibitory Smad7, which we find to be a preferred substrate for WWP2. In the context of a prolonged TGFb-induced EMT differentiation programme over several days, and the apparent disappearance of WWP2-N expression after 4 days of TGFb exposure (see Figure 1b) , the disruption of Smads2/3 Figure 8 A model of WWP2 isoform action on TGFb signalling activity and EMT. In the absence of TGFb, WWP2-N expression causes rapid breakdown of unstimulated Smads 2/3 due to WWP2-N-dependent disruption of WWP2-FL auto-inhibitory interactions. Following TGFb stimulation, WWP2-N is released from WWP2-FL to interact preferentially with Smads 2/3, initially slowing down R-Smad turnover. In the context of a prolonged TGFb-induced EMT differentiation programme over several days, and the apparent disappearance of WWP2-N expression after 4 days of TGFb exposure (see Figure 1b) , the blockade of Smads2/3 interactions with WWP2-FL by WWP2-N would no longer occur, and this would then further stimulate Smad2/3 breakdown as the EMT differentiation programme comes to completion. Finally, expression of the WWP2-C isoform could be responsible for localised temporal activation of the TGFb pathway due to efficient and selective breakdown of inhibitory Smad7.
WWP2 isoforms differentially modulate Smad/TGFb signalling SM Soond and A Chantry interactions with WWP2-FL by WWP2-N would no longer occur, and this would then further stimulate Smad2/3 breakdown as the EMT differentiation programme comes into completion. Finally, expression of WWP2-C could be responsible for localised temporal activation of the TGFb pathway due to efficient and selective breakdown of inhibitory Smad7.
The interconnections between Smad stability and individual WWP2 isoforms reported here could also provide a novel cross-talk mechanism linked to other signalling pathways that might control WWP2 isoformspecific expression. It is likely that WWP2-N is produced by an alternate splicing event that retains intron 9 in the mature transcript, enabling the use of an alternate polyadenylation site and premature stop codon. Regulation of alternate splicing/polyadenylation is a complex and poorly understood biological phenomenon that involves cell/tissue-specific expression of mRNA-binding proteins and splicing factors (Lutz, 2008; Nilsen and Graveley, 2010) . These events are often controlled by extracellular stimuli and growth factor input, and abnormal splice factor activity is often the hallmark of disease states (Danckwardt et al., 2008; Tazi et al., 2009) . It is intriguing that the expression of WWP2-N disappears towards the final stages of TGFbinduced EMT suggesting the existence of mechanisms that tightly control WWP2-N expression, at least during the progression and execution of this cellular differentiation programme. Although the generation of the WWP2-N transcript can be explained by alternative splicing events, the presence of a C-terminal isoform downstream of a TATA sequence and a putative start ATG codon suggests that like other proteins such as transcription factors p53/p73 (Murray-Zmijewski et al., 2006) , WWP2-C isoform may arise because of the presence of intronic promoter activity. Other NEDD4 isoforms, variants of WWP1 and Nedd4-2 lacking the N-terminal regions have been described previously (Flasza et al., 2002; Raikwar and Thomas, 2008) , although these have not been ascribed biological functions. At present, the regulation of WWP2-C expression remains unclear and is the focus of on-going studies, although abundant expression has been detected in chondrocyte cell lines.
Elevated TGFb signalling activity is associated with the pathobiology of many human diseases including fibrosis, heart disease and cancer metastasis. The main findings in this study highlight a key role for WWP2 in TGFb-dependent EMT, and information reported regarding WWP2 isoform-specific interactions with activating Smads2/3 and inhibitory Smad7 could provide a novel approach to selectively moderate levels of R-Smads and I-Smads. Significantly, we have shown that over-expression of an isolated WWP2-WW4 domain can increase cellular levels of I-Smad7 and prevent EMT, presumably by disrupting interactions between Smad7 and both WWP2-FL and/or WWP2-C isoforms. Interestingly, elevating Smad7 levels is known to have therapeutic potential by inhibiting EMT (Valcourt et al., 2005; Javelaud et al., 2007) , and supporting apoptotic events involving TNF, ATM and p53 in hyper-proliferating cells (Zhang et al., 2006; Hong et al., 2007) . Therefore, similar benefits could be achieved in future strategies that specifically target Smad7 interactions with the WW4 domain in WWP2 and/or WWP2-C that would then stabilise inhibitory Smad7 levels.
In summary, this is the first characterisation of a regulatory mechanism involving individual E3 ubiquitin ligase isoforms that modulate TGFb-induced EMT by selectively targeting activating and inhibitory Smads. In future studies, it will be important to address further the biological roles of individual isoforms using misexpression approaches in stable cell lines. Additionally, it will be vital to establish normal and disease expression patterns of all three WWP2 isoforms, with particular emphasis on metastatic disease.
Materials and methods
Antibodies, DNA plasmids, reagents and cell lines Rabbit anti-Smad3 (Chip grade, Abcam, Cambridge, UK), Rabbit anti-Smad2 (Cell Signalling, Danvers, MA, USA), Mouse anti-SMAD7 (New England Biolabs, Hitchin, UK), high affinity Rat anti-HA (Roche, Welwyn Garden City, UK), M2 Mouse anti-Flag (Sigma, Dorset, UK), mouse anti-human vimentin (Sigma), mouse anti-b actin (Sigma) and goat anti-WWP2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as recommended by the manufacturers. Scrambled (SCR) and siRNA for WWP-2 were obtained from Santa Cruz Biotechnology. Plasmids encoding the Flag-tagged derivatives of human WWP2, obtained from Fiona McDonald (University of Otago, The New Zealand), were constructed by PCR cloning into pRK5 followed by the insertion of the Flag coding sequence at the 5 0 terminal. Derivation of human HA-/Flagtagged Smad2, Smad3 and Smad7 is described elsewhere (Wicks et al., 2005) . Human HA-tagged ubiquitin (expressed in pCDNA3.1 þ ) was a kind gift from Dirk Bohmann (University of Rochester, NY, USA). MG132 was purchased from Sigma reconstituted in DMSO and used at 10 mM, and SB431542 was purchased from Tocris Ltd and used at 10-mM concentration. TGFb and Bone Morphogenetic Protein-4 (BMP-4) were from R&D Systems (Abingdon, UK). For bacterial WWP2 expression plasmids, the WWP2 coding sequences were PCR amplified (see Supplementary Information) and cloned into pET28A (Novagen, Nottingham, UK) or pGEX5X-1. Stable expression small hairpin RNA encoding plasmids specific for WWP2-FL were generated by annealing and cloning phosphorylated complementary oligonucleotides into Bgl II cleaved plasmid pTER (see supplementary information), and used to generate stable Colo-357-Tet repressor expressing cells (as described in Levy and Hill, 2005) . Expression was induced by stimulation of cells with 2mM Doxycycline (Melford Laboratories, Ipswich, UK) for 48 h.
Semi-quantitative RT-PCR
Total RNA was isolated from mammalian cells (Promega SV40 Total RNA Isolation, Promega, Southampton, UK) and 1 mg converted to complementory DNA using randomhexamer primers and reverse transcriptase (Invitrogen, Paisley, UK). 1 ml was removed and diluted into 40 ml water, of which 1 ml (1.25 ng) was used as template in a 50 ml reaction using specific primers (see Supplementary Information).
Immunoprecipitation assays
Transfected cells treated with either 10 mM MG132 for 5 h in DMEM medium containing 2% FCS and treated±5 ng/ml TGFb for 1 h, washed in cold PBS, lysed in 1% v/v Igepal-630, 50 mM Tris pH 8.0, 150 mM NaCl, 10% v/v glycerol, 5 mM EDTA, 1 mM NaF, 1 mM Na 3 VO 4 and protease inhibitors (1% NP-40 LB), in the ratio 1 tablet (Roche): 30 ml 1% NP-40LB. Lysates were cleared by centrifugation and incubated with 0.5-mg highaffinity anti-HA antibody (Roche) and 20 ml of protein-G agarose (Sigma) overnight at 4 1C. Immune-complexes were harvested (2000 r.p.m.; 30 s), and repeatedly washed using 0.1% NP-40 LB. Immunoprecipitates were resuspended in 15 ml Laemelli buffer ( þ 10 mM DTT), and samples analysed by western blotting.
Cycloheximide chase HEK293 cells were transfected and after 48 h were pre-treated with 10 mM MG132 for 5 h in DMEM ( þ 2% serum). Cycloheximide (20 mM) was added and cells were incubated for 1 h. The medium was removed and replaced with DMEM medium ( þ 2% serum) and 20 mg/ml cycloxeximide, and cells harvested at specified time points. Cells were washed in icecold phosphate-buffered saline, lysed in 1% NP-40LB and analysed by western blotting.
Bacterial WWP2 expression and in vitro ubiquitination assay WWP2-pET28A protein expression was induced in BL-21 Lys-S (Novagen) cells and proteins purified using Ni-NTA agarose as recommended by the manufacturer (Invitrogen). Approximately 100 ng of each purified protein was incorporated into the in vitro ubiquitination assay using 1 mg of GST-Smad substrate and the quantities of His-Ub, rabbit E1, His-Ub-carrier protein 6 under conditions previously reported (Xu et al., 2004) . Following incubation (30 1C), each reaction was divided into two, and each half was analysed by western blotting for Smad and WWP2.
Luciferase reporter assays
The Smad3 reporter construct (pCAGAC 12 -luc) and the Smad2-specific reporter plasmid DE-luc were kindly provided by Caroline Hill (CRUK Laboratories, London, UK). For each plasmid transfection, 250 ng pCAGAC 12 -luc and 15 ng pRSV-b-galactosidase (pRSV-bgal) encoding plasmid were used in conjunction with Smad encoding plasmids as described previously (Wicks et al, 2005) . Values were averaged, luciferase activity standardised for b-galactosidase activity and data expressed as relative fold changes in luciferase activity over basal activity. A measure of 250 ng of DE-luc, 50 ng pMIXER and 15 ng pRSV-bgal were used in conjunction with other Smad expression plasmids for detection of Smad2-specific activity as described above.
Induction of EMT in Colo-357 cells
Colo-357 cells were seeded at 10 4 cells per 35-mm plastic well (Nunclon, Rochester, NY, USA) and the next day left unstimulated, stimulated with 5 ng/ml TGFb, 5 ng/ml TGFb þ SB431542, and everyday thereafter until day 6 (where the medium was changed every 2 days). Cells were then washed in phosphate-buffered saline, lysed in 250 ml 1% NP40-LB to which 125 ml of 2 Â Lamelli buffer was added and samples were boiled (10 min) and analysed by western blotting.
